- Conditions
- Major Depressive Disorder
- Interventions
- ALTO-300, Placebo
- Drug
- Lead sponsor
- Alto Neuroscience
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 325 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 75
- States / cities
- Phoenix, Arizona • Yuma, Arizona • Rogers, Arkansas + 64 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 121–144
of 2,151
matching trials from the local directory fallback.
- Conditions
- Stereotypical Prolonged Seizures
- Interventions
- Placebo, Staccato alprazolam
- Other · Drug
- Lead sponsor
- UCB Biopharma SRL
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 66
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 50 more
- Conditions
- CRC, Cancer, Colorectal Cancer, Head and Neck Squamous Cell Carcinoma HNSCC, Mesothelioma, Mesothelioma, Malignant, Mesothelioma; Lung, NSCLC, Non Small Cell Lung Cancer, Ovarian Cancer, Ovarian Carcinoma, Ovarian Neoplasms, Pancreas Cancer, Pancreatic Cancer, Renal Cell Carcinoma (Kidney Cancer), Solid Tumor, Adult, Triple Negative Breast Cancer (TNBC)
- Interventions
- Apheresis, Long Range NGS HLA typing, Next Generation Sequencing (NGS)
- Other · Diagnostic Test
- Lead sponsor
- A2 Biotherapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 16
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Duarte, California + 13 more
- Conditions
- Multiple Myeloma
- Interventions
- Linvoseltamab
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 387 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2033
- U.S. locations
- 14
- States / cities
- Miami, Florida • Tampa, Florida • Atlanta, Georgia + 10 more
- Conditions
- Diabetic Retinopathy, Macular Edema
- Interventions
- Aflibercept, MK-8748
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 960 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 28
- States / cities
- Gilbert, Arizona • Glendale, California • Sacramento, California + 25 more
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- VS-7375
- Drug
- Lead sponsor
- Verastem, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 19
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Aurora, Colorado + 13 more
- Conditions
- G12D Mutated KRAS, Pancreatic Ductal Adenocarcinoma (PDAC)
- Interventions
- VS-7375, cetuximab (or panitumumab if α-gal IgE+ or cetuximab reaction)
- Drug
- Lead sponsor
- Verastem, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 185 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 27
- States / cities
- Los Angeles, California • Coral Springs, Florida • Jacksonville, Florida + 21 more
- Conditions
- Lipoprotein(a)
- Interventions
- Enlicitide, MK-7262, Placebo for MK-7262, Placebo for enlicitide
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 750 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 24
- States / cities
- Alexander City, Alabama • Mobile, Alabama • Beverly Hills, California + 21 more
- Conditions
- Major Depressive Disorder
- Interventions
- DT120, Placebo
- Drug · Other
- Lead sponsor
- Definium Therapeutics US, Inc.
- Industry
- Eligibility
- 18 Years to 74 Years
- Enrollment
- 165 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 30
- States / cities
- Little Rock, Arkansas • Orange, California • San Diego, California + 25 more
- Conditions
- BK Virus Infection, BKV Infection, Kidney Transplant
- Interventions
- AIC263029, Placebo
- Drug
- Lead sponsor
- AiCuris Anti-infective Cures AG
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 7
- States / cities
- Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 4 more
- Conditions
- Brain Cancer, Central Nervous System Diseases, GBM, Glioblastoma (GBM), Glioblastoma Multiforme (GBM), Glioma, Newly Diagnosed Glioblastoma
- Interventions
- silevertinib in combination with temozolomide, temozolomide (TMZ)
- Drug
- Lead sponsor
- Black Diamond Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 162 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 35
- States / cities
- Birmingham, Alabama • Springdale, Arkansas • La Jolla, California + 30 more
- Conditions
- Untreated, Unresectable, or Metastatic Colorectal Cancer
- Interventions
- Bevacizumab, CAPOX, FOLFIRI, FOLFOX, Pumitamig
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 990 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2034
- U.S. locations
- 46
- States / cities
- Tucson, Arizona • Springdale, Arkansas • Los Angeles, California + 40 more
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Lunsekimig, Placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 942 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 75
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 59 more
- Conditions
- Ulcerative Colitis
- Interventions
- Duvakitug, Placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 16 Years to 80 Years
- Enrollment
- 980 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 120
- States / cities
- Peoria, Arizona • Scottsdale, Arizona • Tucson, Arizona + 103 more
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- AZD6793, Placebo
- Drug · Other
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 987 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 86
- States / cities
- Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 70 more
- Conditions
- Metastatic Non-small Cell Lung Cancer With MTAP Deletion
- Interventions
- BMS-986504, Carboplatin, Cisplatin, Nab-paclitaxel, Paclitaxel, Pembrolizumab, Pemetrexed, Placebo
- Drug · Other
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 590 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 44
- States / cities
- Anchorage, Alaska • Phoenix, Arizona • Tucson, Arizona + 38 more
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Debio 1562M
- Drug
- Lead sponsor
- Debiopharm International SA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 154 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 7
- States / cities
- Duarte, California • Tampa, Florida • Chicago, Illinois + 4 more
- Conditions
- Pyoderma Gangrenosum
- Interventions
- Placebo matching to spesolimab, Prednisolone, Prednisone, Spesolimab
- Drug
- Lead sponsor
- LEO Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Irvine, California + 23 more
- Conditions
- Myelodysplastic Syndromes
- Interventions
- Elritercept, Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 225 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 25
- States / cities
- Duarte, California • Glendale, California • La Jolla, California + 21 more
- Conditions
- Crohn's Disease
- Interventions
- IV Placebo, IV Tulisokibart, SC Placebo, SC Tulisokibart
- Other · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 16 Years to 80 Years
- Enrollment
- 1,200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 87
- States / cities
- Dothan, Alabama • Phoenix, Arizona • Sun City, Arizona + 72 more
- Conditions
- Relapsed/Refractory Non-Hodgkin Lymphoma
- Interventions
- BMS-986458, Epcoritamab, Glofitamab/Obinutuzumab, Golcadomide, Mosunetuzumab, Rituximab
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 460 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 11
- States / cities
- Phoenix, Arizona • Duarte, California • Jacksonville, Florida + 7 more
- Conditions
- Primary Biliary Cholangitis (PBC)
- Interventions
- Elafibranor, Matched 80 mg placebo
- Drug · Other
- Lead sponsor
- Ipsen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 276 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 43
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • Coronado, California + 32 more
- Conditions
- Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
- Interventions
- Biospecimen Collection, Bone Scan, Computed Tomography, External Beam Radiation Therapy, Magnetic Resonance Imaging, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy
- Procedure · Radiation · Other
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 1,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2041
- U.S. locations
- 424
- States / cities
- Birmingham, Alabama • Tuscaloosa, Alabama • Little Rock, Arkansas + 318 more
- Conditions
- Relapsing Multiple Sclerosis
- Interventions
- Placebo, Ublituximab
- Drug · Biological
- Lead sponsor
- TG Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Cullman, Alabama • Orange, California + 34 more